Adjuvant Treatment With Merck's KEYTRUDAÂ® (pembrolizumab) Demonstrates Statistically Significant &amp; Clinically Meaningful Improvement in Distant Metastasis-Free Survival in Patients With Resected Stage IIB or IIC Melanoma in Phase 3 KEYNOTE-716 Trial
Copyright 2022, Business Wire.
news
2022-06-05 12:00:00

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Adjuvant Treatment With KEYTRUDA Demonstrates Improvement in DMFS in Stage IIB or IIC Melanoma in Phase 3 KEYNOTE-716 Trial
